The UK-based AI technology company Healx has begun a partnership with the Foundation for Angelman Syndrome Therapeutics (FAST), focusing on developing new therapies for the rare neurogenetic disorder.

UK artificial intelligence specialist Healx has begun a partnership with two medical charities that aims to uncover new therapies for the neurodegenerative disease Friedreich's ataxia (FA).

Healx has established itself at the leading edge of this third generation of drug discovery by creating a suite of AI-driven methods that promise to increase the speed, scale and chance of success ...

Healx, an artificial intelligence (AI)-based drug developer focused on treating rare diseases, said it dosed the first patient in a Phase II trial assessing its lead pipeline candidate HLX-1502 in ...